This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Incyte Corporation [INCY], a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs for oncology and inflammation, will visit the NASDAQ MarketSite in Times Square to observe the start of blood cancer awareness month and the launch of a community awareness program, Voices of MPN™, that aims to unite, connect and support people living with MPNs (myeloproliferative neoplasms), a group of closely related blood cancers.
In honor of the occasion,
President and Chief Executive Officer Dr. Paul A. Friedman will ring the Opening Bell. He will be joined by the Incyte leadership team and members of the patient advocacy community.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Tuesday, September 3, 2013 – 9:15 a.m. to 9:30 a.m. ET
Contact: Mariesa Kemble Sam Brown, Inc. for Incyte (608) 850-4745
firstname.lastname@example.orgNASDAQ MarketSite: Christine Barna (646) 441-5310
Christine.Barna@nasdaqomx.comFeed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Opening Bell will be available at:
Photos: To obtain a hi-resolution photograph of the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Incyte Corporation [INCY]:
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs for oncology and inflammation. For additional information on Incyte, please visit the Company's web site at
About NASDAQ OMX Group:
The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets including 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-55 microsecond average speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,300 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit
www.nasdaqomx.com . Follow us on Facebook (
http://www.facebook.com/NASDAQ ) and Twitter (
http://www.twitter.com/nasdaqomx ). (Symbol: NDAQ and member of S&P 500)